Table 3.

Toxicity modifications

Adverse event	Grade 1–2		Grade 3–4		% of patients with G1–4 toxicity during 4/2 schedule	% of patients with G1–4 toxicity during modified schedule	% of patients that obtained at least 1 grade toxicity reduction after switch
	4/2 schedule	Modified schedule	4/2 schedule	Modified schedule
Leucopenia	14	14	2	2	64	64	32
Neutropenia	9	11	7	4	64	60	35
Thrombocytopenia	16	10	2	2	72	48	47
Anemia	12	15	0	1	48	64	6
Asthenia	14	16	5	2	76	72	50
Stomatitis	11	6	1	0	48	24	71
Loss of appetite	16	10	1	1	68	44	58
Cutaneous toxicity	12	12	3	1	60	52	69
Diarrhea	13	15	1	0	56	60	32
Bleeding	9	7	0	0	36	28	50
Arterial hypertension	8	11	8	1	64	48	82
Hypophosphatemia	6	5	0	1	24	24	50
Hypothyroidism	8	7	0	0	32	28	30
Pause symptoms	6	3	1	1	28	16	86
Pain	13	9	2	3	60	48	40
Other	16	16	1	0	68	64	45